Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 1/20 | 0.41 |
| ▸ | TUBB | P07437 | 1/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.41 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.41 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.41 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.41 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.41 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.41 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.41 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.41 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.41 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.41 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 4/20 | 0.40 |
| ▸ | MGLL | Q99685 | 4/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12019911 | 0.95 | TUBB4A (0.44) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29874491 | 0.92 | TUBB4A (0.41) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL21073734 | 0.80 | DGAT1 (0.51) | DGAT1KDM4EALDH1A1MAPTHTT | |
| SCHEMBL29369659 | 0.79 | TUBB4A (0.41) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL20591983 | 0.79 | TUBB4A (0.41) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL23088800 | 0.76 | FAAH (0.34) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1516284 | 0.76 | FAAH (0.34) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL65292 | 0.76 | FAAH (0.34) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29351838 | 0.76 | FAAH (0.34) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Hydrochloric Acid SCHEMBL20241832 | 0.75 | FAAH (0.33) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728304-B1 | SOLID PHASE SYNTHESIS OF ACYLATED PEPTIDES | BACHEM HOLDING AG (CH) | 2025-02-12 | — | — | EP | claimed |
| EP-4320138-B1 | PSEUDO SOLID PHASE PROTECTING GROUP AND METHODS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES AND OLIGONUCLEOTIDE CONJUGATES | BACHEM AG (CH) | 2026-04-01 | — | — | EP | disclosed |
| US-12570679-B2 | STAT3 protein degraders | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-03-10 | — | — | US | disclosed |
| US-12522623-B2 | Small molecule STAT protein degraders | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4605403-B1 | METHOD AND COMPOSITION FOR OLIGONUCLEOTIDE SYNTHESIS | BACHEM HOLDING AG (CH) | 2025-11-26 | — | — | EP | disclosed |
| US-20250282813-A1 | PSEUDO SOLID PHASE PROTECTING GROUP AND METHODS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES AND OLIGONUCLEOTIDE CONJUGATES | BACHEM HOLDING AG (CH) | 2025-09-11 | — | — | US | disclosed |
| EP-4605403-A1 | METHOD AND COMPOSITION FOR OLIGONUCLEOTIDE SYNTHESIS | Bachem Holding AG (CH) | 2025-08-27 | — | — | EP | disclosed |
| US-12240797-B2 | Method of preparing a DON prodrug from L-glutamic acid | DRACEN PHARMACEUTICALS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| EP-3728304-B1 | SOLID PHASE SYNTHESIS OF ACYLATED PEPTIDES | BACHEM HOLDING AG (CH) | 2025-02-12 | — | — | EP | disclosed |
| WO-2024083746-A1 | METHOD AND COMPOSITION FOR OLIGONUCLEOTIDE SYNTHESIS | BACHEM HOLDING AG (CH) | 2024-04-25 | — | — | WO | disclosed |
| EP-4201951-A1 | METHOD FOR PEPTIDE SYNTHESIS | Bachem Holding AG (CH) | 2023-06-28 | — | — | EP | disclosed |
| US-20230159573-A1 | SMALL MOLECULE STAT PROTEIN DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
| US-20230133504-A1 | METHOD OF TREATING GRAFT-VERSUS-HOST DISEASE | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-05-04 | — | — | US | disclosed |
| US-20230083015-A1 | SMALL MOLECULE DEGRADERS OF STAT3 | UNIV MICHIGAN REGENTS (US) | 2023-03-16 | — | — | US | disclosed |
| US-20230057232-A1 | ISOTOPICALLY LABELED BILE ACID DERIVATIVES | INTERCEPT PHARMACEUTICALS, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| US-11472831-B2 | Isotopically labeled bile acid derivatives | INTERCEPT PHARMACEUTICALS, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| WO-2022214692-A1 | PSEUDO SOLID PHASE PROTECTING GROUP AND METHODS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES AND OLIGONUCLEOTIDE CONJUGATES | BACHEM HOLDING AG (CH) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022187417-A1 | SMALL MOLECULE DEGRADERS OF CBP/P300 PROTEINS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-09-09 | — | — | WO | disclosed |
| US-20220185831-A1 | STAT3 PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2022-06-16 | — | — | US | disclosed |
| US-20220089522-A1 | METHOD OF PREPARING A DON PRODRUG FROM L-GLUTAMIC ACID | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089522-A1 | METHOD OF PREPARING A DON PRODRUG FROM L-GLUTAMIC ACID | GLUL, GLRA1, GRIN1 | TUBB4A 4356/4885TUBB 3881/4885TUBA3C 3579/4885 |
| US-20230083015-A1 | SMALL MOLECULE DEGRADERS OF STAT3 | STAT1, STAT3, JAK2 | TUBB4A 3087/4885TUBB 2949/4885TUBA3C 4169/4885 |
| US-20220185831-A1 | STAT3 PROTEIN DEGRADERS | STAT3, JAK2, STAT5A | TUBB4A 2170/4885TUBB 2432/4885TUBA3C 3261/4885 |
| US-12570679-B2 | STAT3 protein degraders | STAT3, JAK2, IL6ST | TUBB4A 2297/4885TUBB 2204/4885TUBA3C 1697/4885 |
| US-12240797-B2 | Method of preparing a DON prodrug from L-glutamic acid | GLUL, GLRA1, GLS | TUBB4A 4385/4885TUBB 3831/4885TUBA3C 3514/4885 |
| US-20230057232-A1 | ISOTOPICALLY LABELED BILE ACID DERIVATIVES | SLC10A2, SLC10A1, NR1H4 | TUBB4A 127/4885TUBB 83/4885TUBA3C 191/4885 |
| US-11472831-B2 | Isotopically labeled bile acid derivatives | SLC10A2, SLC10A1, NR1H4 | TUBB4A 153/4885TUBB 117/4885TUBA3C 187/4885 |
| US-20230133504-A1 | METHOD OF TREATING GRAFT-VERSUS-HOST DISEASE | HLA-DRB1, CD74, HLA-C | TUBB4A 1127/4885TUBB 947/4885TUBA3C 2012/4885 |
| US-20250282813-A1 | PSEUDO SOLID PHASE PROTECTING GROUP AND METHODS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES AND OLIGONUCLEOTIDE CONJUGATES | POLR2H, POLR2E, SUB1 | TUBB4A 3295/4885TUBB 2589/4885TUBA3C 2626/4885 |
| US-20230159573-A1 | SMALL MOLECULE STAT PROTEIN DEGRADERS | STAT1, STAT3, STAT5A | TUBB4A 3076/4885TUBB 2876/4885TUBA3C 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.